From yeast to humans, cell cycle progression and cell division are driven by the sequential activation of a group of serine-threonine kinases called cyclin-dependent kinases (Cdks). Multiple Cdks control the cell cycle in mammals and have been long considered essential for normal proliferation, development and homeostasis. The importance of the Cdk-cyclin complexes in cell proliferation is underscored by the finding that deregulation of the Cdk activity is found in virtually the whole spectrum of human tumors. Recent information from gene-targeted mouse models for the various cyclins and Cdks have made some of the generally accepted concepts of cell cycle regulation to be revised and new and exciting questions to be investigated. Unexpectedly, most of the canonical Cdkcyclin complexes have turned out to be dispensable for cell proliferation due to a high level of functional redundancy, promiscuity and compensatory mechanisms. As a consequence, a "yeast-like" model where only one Cdk is essential to drive all stages of cell cycle progression is starting to be envisioned for mammalian cells. Moreover, the specific molecular players that drive the cell cycle in mammals seem to be cell-type-specific, and new, noncanonical functions of cyclins and Cdks have been revealed. This review will discuss these new findings and their implications for cancer therapy.
ABSTRACT
From yeast to humans, cell cycle progression and cell division are driven by the sequential activation of a group of serine-threonine kinases called cyclin-dependent kinases (Cdks). Multiple Cdks control the cell cycle in mammals and have been long considered essential for normal proliferation, development and homeostasis. The importance of the Cdk-cyclin complexes in cell proliferation is underscored by the finding that deregulation of the Cdk activity is found in virtually the whole spectrum of human tumors. Recent information from gene-targeted mouse models for the various cyclins and Cdks have made some of the generally accepted concepts of cell cycle regulation to be revised and new and exciting questions to be investigated. Unexpectedly, most of the canonical Cdkcyclin complexes have turned out to be dispensable for cell proliferation due to a high level of functional redundancy, promiscuity and compensatory mechanisms. As a consequence, a "yeast-like" model where only one Cdk is essential to drive all stages of cell cycle progression is starting to be envisioned for mammalian cells. Moreover, the specific molecular players that drive the cell cycle in mammals seem to be cell-type-specific, and new, noncanonical functions of cyclins and Cdks have been revealed. This review will discuss these new findings and their implications for cancer therapy.
INTRODUCTION
From early studies in yeast it has been widely accepted that, in all eukaryotic cells, periodic and sequential activation of one or more Cdks, achieved by controlled oscillatory levels of their regulatory subunits, the cyclins, promotes cell cycle entrance from quiescence (G0) and subsequent DNA synthesis and cell division. Unlike yeast where only one Cdk (Cdc28 in S. cerevisiae or Cdc2 in S. pombe) drives all the stages of the cell cycle, sequentially activated by different cyclin partners, in mammalian cells at least four different Cdks (Cdk1= Cdc2, Cdk2, Cdk4, and Cdk6) are associated to cell cycle control and cell division. Four cyclin families are responsible for the activation of the Cdks in different stages of the cell cycle, cyclin D (D1, D2 and D3), E (E1 and E2), A (A1 and A2) and B (B1, B2 and B3). The basic molecular mechanism of cell cycle control has been thoroughly revised elsewhere (1) (2) (3) (4) (5) (6) .
Cdk activity is positively and negatively regulated at multiple levels that, besides activation by binding to the cyclin partner, include phosphorylation and dephosphorylation of specific amino acid residues, subcellular localization, and inhibition mediated by proteinprotein interaction. The complex molecular network that regulates Cdk activity underscores the exquisite control of proliferation that each cell entails to fit into the development program and eventually produce a normal individual. The regulation of Cdk activity has been extensively reviewed (6, 7) .
According to the long prevailing model of cell cycle control in mammalian cells, Cdk4/6-cyclin D andCdk2-cyclin E complexes are sequentially required to promote cell cycle entrance from quiescence, progression through the G1 phase and transition from G1 into S phase in response to mitogenic stimulation. Cell culture and biochemical studies have indicated that both Cdk4/6-cyclin D and Cdk2-cyclin E complexes are essential and rate limiting for the phosphorylation and inactivation of the tumor suppressor protein retinoblastoma (pRb) and subsequent induction of the E2F-dependent transcriptional program required for entering S-phase (8) . More recently another Cdk, Cdk3, activated by binding to cyclin C, has been shown to be potentially involved in exit from quiescence by contributing to early pRb phosphorylation (9) . However the role of Cdk3 in cell cycle control is still not completely understood as this gene is not expressed in many cell types and is mutationally inactivated in the mouse genome (10) .
Progression through S-phase seems to be also dependent on Cdk2-cyclin E complexes as well as on cyclin A that binds and activates both Cdk2 and Cdk1 (during S phase and in G2 respectively). Finally, activation of Cdk1 by cyclin B promotes mitosis and cell division. Inactivation of Cdk1 late in mitosis by proteasomemediated cyclin B degradation contributes to exit mitosis and re-enter G1. This model has been widely accepted as an archetype of cell cycle regulation for most if not all mammalian cell types.
Interestingly, in humans the Cdk protein family includes 20 members, 11 of which are homologous to the originally discovered Cdc28 protein of S. cerevisiae (reviewed in 11). The function of most of these other Cdks is still poorly understood. Whether some of them are involved in some aspects of cell cycle regulation or could functionally replace some of the canonical cell cycle Cdks needs further investigation (12) .
Recently the generation of mouse strains, in which individual or multiple cyclin or cdk genes have been inactivated by gene targeting, has provided data that challenge several aspects of this canonical model leading to a more accurate view of cell cycle control in mammals .
DISCUSSION

G1/S control in mammalian cells: the basic model
Cells make the commitment to proliferate or not during the G1 phase of the cell cycle. The extracellular environment, by means of nutrient availability, cell-cell interaction, survival factors and mitogenic signalling dictates whether a resting (G0) cell eventually resumes proliferation. This is a very complex and still poorly understood process which impinges onto the cell cycle apparatus at many levels, one of them being the activation of the Cdk4/6-cyclin D complexes.
Unlike other cyclins, the early G1 D-type cyclin family is mostly regulated by mitogen induced signal transduction pathways, which not only promote their synthesis but subsequently control: a) their activity by modulating cyclin D translation and stability, b) their assembly with the Cdk partners Cdk4 and Cdk6, and c) the subcellular localization of the resulting heterodimers (13) . Given the reduced half-life of the three D-type cyclins (14) , mitogen withdrawal is rapidly followed by a reduction in the net cyclin D-dependent kinase activity, which becomes a simple and yet finely tuned oscillator mechanism that governs early G1 progression. Cyclin D turnover is also inhibited by growth factors since cyclin D degradation by the proteasome depends on the phosphorylation of threonine 286 by glycogen synthase kinase-3beta, a process that can be repressed by the PI3K/Akt signalling pathway (15) . Therefore, growth factors not only induce cyclin D synthesis but also prevent its degradation.
Besides cyclin D levels, the cell cycle inhibitors of the INK4 family (p15 INK4b , p16
INK4a
, p18
INK4c and p19 INK4d ) also contribute to regulate cell cycle entrance from quiescence in response to the cellular environment. These proteins are allosteric competitors of the D-cyclins for binding to Cdk4 and Cdk6. They act as brakes for G1 progression in response to different factors such as mitogen withdrawal, proliferation inhibitors like TGF-beta, differentiation signals, oncogenic stress or senescence (16).
If mitogenic signalling prevails, the newly synthesized cyclin D pool assembles into Cdk4 and Cdk6 holoenzymes and promotes cell cycle progression by negatively regulating the so-called pocket proteins (pRb, p107 and p130). The unphosphorylated forms of these three pRb family members repress transcription from E2F-responsive promoters at different levels (17) . This inhibitory effect is first mediated by binding to (and thus blocking) the activation domain of the transcription factor. Additionally this interaction impedes the formation of the pre-initiation complex within the promoter region. The pRb protein also functions as a landing pad for the recruitment of chromatin-modifying enzymes resulting in a hostile environment for active transcription (18) . Conceptually, the relevance of this mechanism for G1 phase control was recently underscored by the characterization of Whi5, the so far elusive pRb orthologue in S. cerevisiae, describing a functionally equivalent pathway in yeast (19) .
The phosphorylation of pRb family members by Cdk4/6-cyclin D complexes partially alleviates their transcriptional repressor activities. This occurs in a subset of E2F responsive promoters at mid-G1 and results in the transcription of cyclin E and also cyclin A2 among many other genes. The mechanism that underlies the differential response of E2F promoters to Cdk4/6-cyclin D, and the factors that mediate it, are still unresolved issues. In any case, this is a key event in the progression through the G1 phase as the accumulation of cyclin E-dependent kinase activity above a certain threshold marks out a point of no return from which a cell is committed to division and proceeds towards DNA synthesis.
This stage of the cell cycle was initially described as the restriction point, defining a G1 step when growth factor dependency ends and cell proliferation irreversibly switches to a mitogen independent fashion (20) . In molecular terms it is accomplished by the formation of Cdk2-cyclin E complexes, which conclude the inhibitory phosphorylation of pRb previously initiated by cyclin Ddependent kinases. The linearity of this pathway has been experimentally proven and it is further supported by genetic evidence. For instance, cyclin E overexpression renders proliferation of rat fibroblasts independent of both cyclin D and the phosphorylation state of pRb (21) . More importantly, all defects associated to cyclin D1 deficiency are rescued by cyclin E cDNA when knocked-in into the cyclin D1 genomic locus (22) or by ablation of the Cdk2 inhibitor p27
Kip1 (23) . As a consequence, cyclin E expression increases from the restriction point reaching a maximal peak concomitantly to S phase entry.
However, the activation of Cdk2-cyclin E complexes does not merely rely on the increased transcriptional rate of the cyclin counterpart. In this scenario, Cdk-cyclin D complexes play an additional and non-catalytic role in G1 progression that also contributes to the activation of Cdk2-cyclin E. The Cip/Kip family of proteins (p21 Cip1 , p27 Kip1 and p57 Kip2 ), true inhibitors of the Cdk2-cyclin E complex, keeps the newly formed Cdk2-cyclin E inactive by forming heterotrimeric complexes and interfering with the kinase activity. These inhibitors also bind to Cdk4/6-cyclin D complexes without causing a reduction in their enzymatic activity, at least at stoichiometrical levels. Several lines of evidence suggest that p21
Cip1 and p27 Kip1 actually play a positive role by stabilizing and facilitating the nuclear import of Cdk-cyclin D complexes (24) . Although the dependency on Cip/Kip proteins for the Cdk-cyclin D activation is a controversial issue (25) , it is generally believed that by titrating these inhibitors away from Cdk2-cyclin E, cyclin D-dependent kinases promote cell cycle progression independently of their enzymatic activity (6) .
Completion of pRb phosphorylation by Cdk2-cyclin E allows for the full activation of the E2F transcriptional program and the synthesis of a plethora of factors required for the successful completion of subsequent phases of the cell cycle (26) .
It is now becoming evident that the straight and linear input of the different Cdk-cyclin complexes on G1 progression depicted above is clearly an oversimplification. Cyclins and Cdks also function in other parallel pathways with a direct influence on cell proliferation. Until recently, the only documented substrates of the cyclin D-dependent kinases were pRb and the related proteins p107 and p130. However, recently, both Cdk4 and Cdk2 have been shown to antagonize TGF-beta -mediated growth inhibition by phosphorylating Smad3 (27) . This means that G1 Cdks directly promote proliferation by revoking the activities of at least two families of transcriptional repressors. In this respect, it will be interesting to address whether pRb ablation or silencing may eliminate the need for Smad3 phosphorylation.
What is more, D-type cyclins play additional Cdk-independent functions and are involved in a complex network of interactions that modulates transcription of many genes. They do so by direct interaction with transcription factors and components of the transcriptional machinery such as the estrogen receptor or Myo D (28) .
Unlike Cdk4/6-cyclin D complexes for which a relatively short number of substrates have been so far identified, many proteins have been found to be phosphorylated by Cdk2-cyclin E, including itself (cyclin E is phosphorylated by the Cdk2-cyclin E complex) and its inhibitor p27 Kip1 . Phosphorylation by Cdk2 contributes to p27
Kip1 downregulation at the G1/S transition, by inducing its proteosome-mediated degradation, and therefore contributes to increasing Cdk2 activity at this crucial stage of the cell cyle by a self-activating mechanism (29, 30) . On the other hand, phosphorylation of cyclin E by the Cdk2-cyclin E complex also contributes to the degradation of cyclin E in a proteasome-dependent fashion once S phase is initiated, favoring the switch of Cdk2 activity to that of Cdk2 complexed with cyclin A (31).
The Cdk2-cyclin E complex also phosphorylates other proteins involved in centrosome duplication, initiation of DNA synthesis and induction of histone gene transcription (32) . The physiological relevance of these phosphorylation events, whether or not they actually take place in vivo, and their connection with cell cycle progression are still poorly understood. Nevertheless, taken altogether, these data have supported the concept of a nonredundant and essential function of Cdk2-cyclin E as the master key for entering S-phase, coordinating cell cycle progression with other critical cellular processes such as initiation of DNA synthesis, centrosome duplication and chromatin assembly at the G1/S transition.
Our understanding of cell cycle regulation in mammalian cells for many years has relied on tissue culture studies and biochemical in vitro approaches. These studies have been historically hampered by the high level of functional redundancy among different family members, and the technical difficulty for interfering specifically with a particular protein without disturbing the normal function of other family members or even other functionally unrelated proteins. The recent generation of gene targeted loss of function mouse models for individual cyclins and Cdks, or different combinations of them, has provided information about the physiological function of each one of these proteins in development and cell homeostasis.
CDK4/6-cyclin D signalling in mouse development and cell proliferation
All three D-cyclins (D1, D2, D3) have been individually eliminated in the mouse by gene targeting. The three combinations of double knock-out mice, expressing only one of the D-cyclins, and the triple knock-out mice lacking cyclin D-dependent signalling, have also been generated by intercrossing the single knock-out mice (Table 1) . In parallel the cyclin D catalytic subunits, Cdk4 and Cdk6 have been ablated in the mouse by gene targeting, and the double knock-out mice have also been generated ( Table 2) . In this section we will summarize the most important findings related to the function of Cdk4/6-cyclin D in the control of mouse development based on the information obtained from the phenotypical characterization of these gene targeted mouse strains.
Individual D-cyclins are essential in specific cell types
Throughout most of the embryonic development and in the adult, expression of each of the D-type cyclins occurs in a tissue-specific although greatly overlapping manner (33) . Thus, the consequences derived from the ablation of each one of the three D-cyclins in the mouse may be alleviated by any of the two remaining family members. Indeed, that would seem to be the case in light of the very limited developmental abnormalities found in single D-type cyclin knock-out mice (34) (35) (36) (37) (38) (39) . All three single knock-out strains are viable with only tissue specific defects often circumscribed to very particular cell types (Table 1) .
However, as the three single cyclin D knock-out models are germ line knock-outs, where the genes are constitutively inactivated, compensatory mechanisms during embryonic development may also contribute to explain the mild phenotypes of these mice. The existence of such compensatory mechanisms, often vaguely defined as embryonic plasticity or developmental compensation, was unambiguously demonstrated for the D-cyclin gene family by Ciemerych and co-workers by generating "singlecyclin" mice, where all the different combinations of two out of the three D-cyclins are constitutively inactivated in mice (40) , and proliferation of specific cell types becomes critically dependent on the remaining intact D-cyclin. The analysis of the embryonic development of such singlecyclin mice showed that in these animals the typical tissuespecific pattern of D-cyclin expression was not maintained and the knock-out embryos displayed ubiquitous expression of the remaining intact cyclin. Interestingly this "compensation" is somehow achieved by different molecular mechanisms in different embryonic tissues. In some of them compensation relies on altered transcriptional regulation, such that an increase in the mRNA level of the remaining cyclin is observed, whereas in other tissues it depends on posttranslational pathways (40) . In any case these results clearly show that during embryogenesis, cellular proliferation relays on net cyclin D activity and the three family members are essentially functionally exchangeable in most, if not all, cell types.
Conclusions from the analysis of adult singlecyclin mice are in essence equivalent. Whereas cyclin D1-only animals die during late embryogenesis, cyclin D2-only and D3-only mice are viable and some survive for several weeks with the majority of organs showing no apparent defects (40) . Interestingly, the double knock-out mice do not show new phenotypes, but the sum of the ones observed in mice lacking the individual cyclins. Just like the embryonic cycles, proliferation of adult cells not only requires the remaining D-type cyclin but also the ability to up-regulate its expression in tissues where, under normal circumstances, it would be absent or expressed at reduced levels. Failure to achieve enough expression of the remaining cyclin D results in tissue-specific defects with variable penetrance depending on the nature of the remaining cyclin. Remarkably, these defects were traced to the inability of specific transcription factors to specifically up-regulate the remaining cyclin in a particular tissue. Still, whether at least in these defective tissues there are inherent properties unique to each specific cyclin is still a possibility that cannot be totally ruled out.
However, recent work from the Sicinski´s laboratory has provided further insight in this direction. Cyclin D1 deficient mice showed the most severe phenotype of the three single knock-out strains and displayed postnatal lethality, reduced body size, hypoplastic retina, neuropathy and defective breast development during pregnancy (34, 35) . Carthon and coworkers have now generated a knock-in mouse strain in which cyclin D2 is expressed in place of D1 and shown that, with the exception of the mammary glands where cyclin D2 fully corrects the cyclin D1 null phenotype, the rescue of other phenotypes is incomplete (41) . Thus, while it seems that the distinction between these two cyclins (and possibly between all three family members) relies mostly on their tissue-specific expression pattern, still subtle functional differences exist. This, in turn, may be essential for the delicate temporal and spatial regulation of proliferation and development in such a variety of coexisting cell types.
Cdk4 or Cdk6 ablation in the mouse: the other side of the coin
Concurrently with the above findings, mouse strains devoid of the catalytic partners of the D-type cyclins have been generated. Cdk4 and Cdk6 are considered ubiquitous enzymes, co-expressed in most cells along all stages of development. However, lack of reliable antibodies for these proteins impairs a thorough characterization of their expression pattern by immunohistochemical techniques. Individual Cdk4 and Cdk6 defective mice are viable and only show tissue-specific defects similar to those observed in the single cyclin D knock-outs, underscoring the robust functional correlation between these two protein families (Table 2) .
Cdk4 knock-out mice are viable albeit with reduced body size, resembling in this aspect the phenotype of cyclin D1 null mice (42, 43) . They exhibit defects in specific subsets of endocrine cells. Males have reduced numbers of Leydig cells and decreased fertility. Females are sterile as a consequence of low counts of anterior pituitary cells that results in prolactin deficiency, abnormal estrus cycle and impaired pregnancy (44, 45) .
But the most striking phenotype in these mice is a severe defect in another endocrine cell type. Cdk4 knockout animals show a dramatic reduction in the numbers of insulin-producing beta cells resulting in the early onset of insulin-dependent diabetes and therefore limited lifespan (42, 43) . Remarkably, Cdk4 deficiency does not affect neogenesis of beta cells during embryonic development but becomes essential for a proliferative burst of this cell type in late gestation and postnatal development (45) . Interestingly, a knock-in strain that expresses endogenous levels of a mutant form of Cdk4 that is resistant to inhibition by INK4 proteins (Cdk4R24C), develops beta cell hyperplasia and insulinomas with age (42, 46) underscoring the importance of the regulation of the Cdk4 activity for beta cell proliferation. This knock-in strain develops additional phenotypes that are discussed in a latter section of this article.
The strong dependence on Cdk4 for postnatal beta-cell proliferation is probably mostly attributable to the virtually lack of Cdk6 expression in pancreatic beta cells (45) and therefore the complete reliance of this cell type on Cdk4 activation to enter the cell cycle. Alternatively, the existence of a specific function of Cdk4 in postnatal beta cells can not be totally ruled out. An attempt to rescue the beta cell phenotype by expressing a Cdk6 transgene specifically in beta cells of mice lacking Cdk4 is in progress in our laboratory and will help to resolve that issue.
Among the D-cyclins, cyclin D2 is the one that is more abundantly expressed in beta cells (45) , and it is reassuring to learn that mice lacking cyclin D2 also have impaired beta cell proliferation and develop diabetes, albeit less severe than Cdk4 null mice (47) . This is likely due to functional redundancy of cyclin D2 with cyclin D1, as the loss of a functional cyclin D1 allele, in mice lacking cyclin D2, exacerbates the diabetic phenotype (48) . Therefore, it seems that beta cells depend mostly on the Cdk4-cyclin D2 complex to proliferate in response to metabolic needs. The implications that this may have in terms of developing new therapies for beta cell regeneration of diabetic patients are starting to be explored.
The reduced body size phenotype in Cdk4 deficient mice deserves additional attention. This phenotype is caused by a reduction in the total number of cells rather than to an overall decrease in cell size. In an attempt to rescue the Cdk4 null phenotype, Cdk4 knock-out mice, that have a targeted inactivation of the Cdk4 gene by insertion of a floxed PGK-neo cassette into the first intron and in opposite transcriptional orientation to the one of the Cdk4 gene, were crossed with a transgenic mouse line in which the Cre recombinase is expressed under the control of the rat insulin gene promoter (RIP) (45) . This line expresses Cre in beta cells and in the primordial pituitary (the Rathke pouch) during embryonic development. The Cre-mediated excision of the neo cassette, restored the endogenous expression of Cdk4 specifically in beta-cells and in the pituitary of Cdk4-deficient mice. This genetic approach effectively rescued the diabetes and female sterility phenotypes but the animals remained small, with identical body size to that of Cdk4 knock-out mice (45) . Therefore, the reduced body size phenotype is not a secondary effect of the endocrine malfunction, but rather a defect caused by a reduced proliferation rate of most cell types in the body in the absence of Cdk4 (45) . It is then tempting to speculate that this is a cell autonomous phenomenon and that Cdk4 may play a role in establishing homeostatic cell numbers. Remarkably, ablation of the Cdk4 locus in Drosophila results in a very similar outcome. Cdk4 deficient flies develop and eclose normally but are smaller due to reduced cell numbers (49) . As cyclin D1 null mice exhibit the same small size phenotype, it is likely that control of cell numbers in mammals relies mostly on Cdk4-cyclin D1 activation by mitogenic signalling.
Animals devoid of Cdk6 have also been generated. They show the least compromised phenotype of all the single D-cyclin and D-cyclin-dependent-Cdk knockout models. Intriguingly, only females have marginally reduced body size but are fertile and show a normal life span. Males have normal body size and are fully fertile. Animals of both sexes exhibit mild defects in some haematopoietic compartments. For instance, thymus and spleen are hypoplastic, showing a specific dependence of lymphatic tissues on Cdk6 for normal development (50) .
Perhaps the most logical explanation for these narrow phenotypes in Cdk4 and Cdk6 deficient mice, again comes from the high structural and functional homology between these two kinases that would result in their in vivo functional redundancy, at least in those tissues where both proteins are expressed. Although this may be at least partially true in some cell types, an alternative explanation to account for the absence of extreme phenotypes in the cyclin and Cdk deficient strains described above is that proliferation and differentiation of certain (if not the majority) of cell types can be brought about in a Cdk4/6-cyclin D-independent manner.
Most of the embryonic tissues are Cdk4/6-cyclin-D independent
According to our current understanding of the core cell cycle machinery, D-type cyclins are regarded as essential mediators of extracellular signalling. Therefore, the hypothesis stemming from the results depicted above, that at least some cell types might proliferate in a cyclin D autonomous fashion, required unambiguous genetic support. This has now taken form in two recent studies from the Barbacid and Sicinski groups providing genetic evidence that many cell types of the developing embryo indeed proliferate normally in the absence of Cdk4/6-cyclin D complexes.
Kozar and coworkers inter-crossed cyclin D1, D2 and D3 deficient mice in an attempt to generate triple knock-out embryos. Surprisingly, conceptuses lacking all D-cyclins developed until mid/late gestation without any overt evidence of pathology (51) . In a parallel set of experiments, Malumbres et al. reported the effect of eliminating both Cdk4 and Cdk6 genes in the mouse (50) . On balance, the phenotype of the double Cdk4/6 null mice reassuringly mirrors that of cyclin D deficient animals and viceversa. In both cases embryos begin to die in utero at E14.5, i.e., a time when many organs are well developed. Although none of the D-cyclin null embryos progress further than E17.5, a number of Cdk4/6 deficient embryos do, and actually some even complete the gestational period only to die soon after birth. In both cases the cause of death is attributed to multilineage haematopoietic abnormalities resulting in a severe megaloblastic anemia. In accordance with this finding, the numbers and the proliferative capacity of all haematopoietic stem cells from fetal livers, are drastically reduced both in vivo and in vitro. With the only exception of a ventricular septal defect, not present in the Cdk4/6 double mutant mice, the fact that the very same cellular compartment, the hematopoietic tissue, is affected in both groups of mice provides genetic evidence that the main function of the Dtype cyclins in development is to activate Cdk4 and Cdk6. It is important to note though, that knock-out embryos of both strains show reduced body size, highlighting the significance of these Cdk-cyclin complexes in controlling cell growth, cell proliferation or both. However, the tantalizing finding that the majority of cell types can arise in the absence of such complexes has challenged our understanding of cell cycle regulation. Or has it not?
In this respect, it is important to keep in mind that the most drastic consequences of the absence of Cdk4/6-cyclin D complexes arise in tissues with a high proliferative demand like the fetal haematopoietic compartment. Some precedent for this finding exists; mice devoid of Bmi-1, a repressor of the Cdk4/6 inhibitor p16 INK4a , display impairment of haematopoietic proliferation and T-cell development (52) . Also cyclin D3 null T-cell progenitors are severely crippled in their ability to undergo pre-TCR expansion (37) . Finally, Cdk4 null animals fail to undergo the proliferative burst of pancreatic beta cells during late embryogenesis (45) . The characterization of the cell autonomous differences between Cdk4/6-cyclin Ddependent and -independent tissues will obviously help to better understand how mammalian cell cycle is regulated, but a priori it seems that different cell types may require different thresholds of cyclin-dependent kinase activity for efficient proliferation. "Turbo-proliferative" tissues, such as the fetal hematopoietic compartment, may have a very high threshold, that can not be reached in the absence of cyclin D-dependent signalling.
Altogether, one synthesis of these findings is that the so-called plasticity or developmental compensation may comprise a plethora of different but not mutually exclusive mechanisms that cooperate to promote proliferation. At the end of the day, the exact combination of these redundant pathways that is activated in each particular cell type will likely reflect their different proliferative requirements (Figure 1 ). This, of course, underlies a critical issue in cancer biology and may be related to the exquisite tissue selectivity for specific mutations (and combinations of them) during tumor progression, a process which we are only beginning to unravel (53).
Mouse embryonic fibroblasts (MEFs) lacking cyclin D-dependent signalling can cycle
The vast majority of the experiments that support the central role of Cdk4/6-cyclin D complexes in the response to the extracellular mitogenic environment involve interfering with Cdk activity in vitro by a variety of methods which include: chemical inhibitors, expression of dominant negative Cdk mutants, microinjection of neutralizing antibodies, overexpression of Cdk negative regulators and the use of antisense oligonucleotides (reviewed in 13). While having in mind the technical limitations of these experimental approaches, mounting evidence has accumulated to substantiate an indisputable function of Cdk4/6-cyclin D in promoting G1 progression. Experiments performed in vitro with primary cultures derived from the compound mutant mice are illuminating as allow for the direct testing of this function of D-cyclin signalling with much less technical caveats.
Cdk4/6 double knock-out and D-cyclins null primary MEFs display a decreased rate of proliferation in culture, which is aggravated with time, resulting in a premature senescent phenotype. Even when these cells, as expected, are resistant to the Cdk4/6-cyclin D inhibitor p16 INK4a (one of the major mediators of the cell cycle arrest experienced by senescent cells) their life span in vitro is compromised by the lack of D-cyclin dependent signalling. In any case, the proliferation of asynchronous fibroblasts of both genotypes, under continuous mitogenic stimulation, proceeds reasonably unaffected (50, 51) .
Considering the previously ascribed functions for the ablated proteins as major intracellular sensors for mitogenic signalling, the analysis of G0 exit in response to growth factors in MEFs lacking D-cyclins or Cdk4 and Cdk6 was an absolute requisite. In this approach cells are rendered quiescent by serum deprivation and re-entry into the cell cycle is analyzed after arrested cultures are re-stimulated with 10% serum. In every experiment mutant cells failed to respond as efficiently as the controls to the mitogenic stimuli and only a subset of cells resumed proliferation. This phenotype was exacerbated when cells were stimulated with lower concentrations of serum causing the appearance of more severe cell cycle re-entry defects. Remarkably, in these assays the cells that did respond to the proliferative stimuli appeared to complete cell division with normal kinetics indicating that Cdk4/6-cyclin D complexes are not essential for mitogen induced cell cycle entrance from G0, although they do play a role in this process (50, 51) At a molecular level, the proliferation defects in both groups of mutant cells correlated with a significant reduction in the overall levels of pRb phosphorylation during cell cycle re-entry and a concomitant delay in the activation of E2F targets. Several consensus Cdk target sites exist on pRb but their kinase specificity and, specially, their functional implications still require more in depth characterization. The prevailing model in the field assumed that phosphorylation of Cdk4/6 specific sites would precede pRb phosphorylation by Cdk2 (54) . However, while phosphorylation of a range of Cdk4/6 specific sites was significantly diminished in the knock-out cells this was not the case for T-821, a known Cdk2-cyclin E and -cyclin A specific residue (50, 51) . Altogether these results suggest that pRb phosphorylation on the cyclin E-and A-specific sites, not only is independent of Cdk-cyclin D complexes but it is also sufficient to functionally inactivate its repressor activities, allowing for the activation of E2F targets and cell cycle progression. In fact, shRNAs directed to Cdk2 in both double-Cdk4/6, and triple-cyclin D deficient MEFs strongly inhibited cell proliferation while having a marginal effect on wild-type cells. Interestingly, in these cells the activity of Cdk2 was not diminished in spite of the fact that free p27
Kip1 can not be sequestered by Cdkcyclin D complexes. This may be in part due to the fact that overall levels of p27 Kip1 , and also of p21 Cip1 at least in Cdk4 and 6 deficient cells, happen to be reduced compared to wild-type counterparts (50).
On balance, although still lacking genetic confirmation, in the absence of cyclin D-dependent kinase activity, cell proliferation seems to become absolutely dependent on Cdk2. In this respect it is also interesting to note that in the absence of Cdk4 and 6 there is an increased association of cyclin D to Cdk2, and in agreement with previous reports (55) these complexes show pRb kinase activity (50) . This in turn may partially compensate for the absence of Cdk4 and 6 and explain the slightly delayed embryonic lethality and milder haematopoietic defects shown in Cdk4/6 deficient mice compared to cyclin D-null animals.
An interesting argument raised by the above mentioned experiments is the existence of Cdk4/6-cyclin D-independent mechanisms that connect the activation of cyclins E and A to the extracellular environment. Earlier experiments showed that overexpression of a nonphosphorylatable form of pRb only induced a transient G1 arrest, and in this scenario induction of cyclin E was achieved via a c-Myc-dependent pathway (56) . It is currently unknown whether other parallel pathways functionally coexist in mammalian cells, but Cdk4/6 double knock-out-and cyclin D-null cells will help to address this issue.
CDK2-cyclin E signalling in mouse development and cell proliferation
Elucidation of the importance of Cdk2-cyclin E signalling in cell cycle control in vivo has been made possible by the generation of individual knock-out mice lacking either cyclin E1 or E2, and the double knock-out mice lacking both E-type cyclins. In parallel, Cdk2, the only so far known catalytic partner of the E-cyclins, has been also inactivated in mice by gene targeting (Tables 1   and 2 ). The phenotypical characterization of these mice has also provided unexpected results that will be discussed in this section.
Cdk2 is dispensable for somatic cell proliferation and development
As discussed above, Cdk2 and its activators the E-type cyclins have been long considered essential regulators of the mammalian somatic cell cycle. The general thinking was that these proteins were required for promoting and coordinating not only the G1/S transition but also chromosome and centrosome duplication, histone synthesis and chromatin assembly. Recent work from different laboratories, including ours, has utterly challenged this model and showed that these seemingly essential molecules are dispensable for mouse development and cell proliferation.
The first surprising setback to the up to then prevailing model took form when depletion of Cdk2 through antisense oligonucleotides or siRNA, opposite to what had been previously reported and generally accepted from very similar experimental settings (57), was shown to have a negligible effect on the proliferation of colon cancer cell lines (58) . However, a note of caution was raised to the generalization of Cdk2 dispensability as cancer cells often have anomalous cell cycle regulation that could result in compensatory mechanisms by the action of other misregulated pathways (59) . This uncertainty was erased immediately afterwards when Ortega and co-workers reported the targeted gene inactivation of Cdk2 in the mouse. Unexpectedly, Cdk2 null mice are fully viable and, with the exception of a dramatic meiotic failure, show no sign of developmental abnormalities indicating that this kinase was truly dispensable for the majority, if not all, of somatic cells (60, 61) .
In fact, unexpectedly, Cdk2 knock-out mice are the least affected of all the cyclin and Cdk deficient strains generated so far in terms of somatic cell phenotype, and have a lifespan equal to that of wild-type littermates. Cdk2 dispensability, however, does not necessarily imply that this kinase does not perform central (although not essential) functions in cell proliferation and embryonic development. Likewise, compensatory mechanisms could play a role in substituting Cdk2 function raising the question of how its absence may be balanced in such an immense variety of cellular settings. However, the Cdk2 knock-out allele generated by Ortega and co-workers is a conditional allele (Cdk2 fl ). Cre-mediated inactivation of Cdk2 in primary cultures of Cdk2 fl/fl mouse embryonic fibroblast has no effect on cell proliferation, therefore arguing against compensatory mechanisms activated by developmental plasticity during embryonic development (60) .
It is tempting to speculate that in the absence of Cdk2 cell cycle progression might be driven by other G1 kinase, mainly Cdk4. For instance, upon Cdk2 depletion Cdk4 phosphorylates some of the "Cdk2-specific" sites on pRb (58) . The converse situation is also true. As previously mentioned, in the absence of Cdk4/6-cyclin D, pRb phosphorylation is reduced but not eliminated (50, 51) and Figure 2 . New functions of cyclin E and Cdk2 revealed by gene targeted mouse models. Cyclin E promotes entrance in S-phase from quiescence (G0) and DNA endoreplication in trophoblast-derived placental giant cells and megakaryocytes in a Cdk2-independent manner. At the G0 to S transition cyclin E is required for the recruitment of the MCM complex to the PRCs at the origins of DNA replication, while Cdk2 is not. The catalytic partner of cyclin E in these processes is unknown. Cdk2 is essential in spermatogenesis for progression of prophase I beyond pachytene, and for survival of oocytes beyond diplotene, also at prophase I. The cyclin(s) that activate Cdk2 at different stages of meiosis are still unknown. Cdk2 may have other functions at later stages of meiosis.
proliferation becomes dependent on Cdk2 activity. Additionally, just like Cdk2, Cdk4-cyclin D1 associates to the pre-replicative complex at origins of DNA replication (62) . Therefore, the degree of built-in redundancy of the system may be much higher than anticipated to the extent that a single G1-Cdk might suffice to promote cell proliferation (Figure 1) . Indeed, Cdk2/6 double knock-outs are perfectly viable and show no sign of pathology throughout their entire lifespan (50), indicating that Cdk4 by itself is able to drive normal cell proliferation, development and homeostasis. Genetic linkage between Cdk2 and Cdk4 has so far precluded the generation of Cdk2/4 double knock-out mice, but in the light of the above mentioned results it will be very interesting to asses whether Cdk6 alone can sustain G1 progression and promote exit from quiescence.
Considering that D-cyclins, Cdk4, Cdk6, Cdk2 and also cyclin E ( see below) are all dispensable for cell proliferation another conceivable scenario would be one in which concatenation of unperturbed mitotic cycles could be driven by Cdk1 alone associated to A-or B-cyclins (63), or stretching the dogma a bit further, Cdk1-cyclin B in solo would just do the job. In this respect, cyclin B1 is sequestered in the cytoplasm and translocates into the nucleus in prophase (64) . However, using a Xenopus cell free system Moore and co-workers have recently shown that if cyclin B1 is prematurely relocated into the nucleus it can then successfully promote DNA replication (65) . This is reminiscent of the cell cycle in yeast where a single mitotic cyclin allows ordered progression through the cell cycle (66) . However, the simplicity of alternating rapid S and M phases during the syncitial phase of early development in Xenopus or Drosophila is difficult to reconcile with a far more complex setting such as the developing mammalian embryo. Even in budding yeast, cell cycle regulation is not that undemanding and S and M cyclins are not equally interchangeable due to subtle substrate specificity (67) . Maybe other Cdks, not directly implicated in cell proliferation control, may come into play in a situation where "canonical" cell cycle Cdks are absent. As an example Cdk9 is able to bind and phosphrylate pRb (68) and Cdk3, although inactive in all mice laboratory strains due to a point mutation, has been recently found to play a role in promoting G0 exit (9) .
Finally, there is a substantial degree of homology between the Cdks and other kinases (69) of which only a minority have been sufficiently studied, and thus could also cooperate in cell cycle regulation (70) . Whether any of these kinases may account for a Cdk-independent mechanism promoting G1 phase progression and to what extent they are related to the still undefined mechanisms of the so called "functional compensation" still requires much more effort to elucidate.
Cdk2 is essential in meiosis
The meiotic defect of the Cdk2 knock-out mice deserves additional comment. Although the male and female phenotypes differ, both sexes are completely infertile with a 100% penetrance.
Male germ cells do not progress beyond the pachytene stage of prophase I. At this stage primary spermatocytes undergo apoptosis probably as a consequence of defective synaptonemal complex formation both at the level of axial/lateral and central elements (60) . Oocytes however, progress normally through pachytene where they show normal synapsis and continue further to the late diplotene or dictyate stage where they die by apoptosis, such that in the first week of age the ovaries of Cdk2 null females are devoid of oocytes.
Heterodymorphic meiotic phenotypes are common in genetic modified mice demonstrating sexual divergence in the molecular control of the meiotic cycle. Nevertheless the phenotype of Cdk2 null mice indicates that Cdk2 is essential for germ cell development beyond meiotic prophase I, both in males and in females (Figure 2) . Interestingly, although some kind of meiotic collapse is a common phenotype in most mouse models missing cell cycle regulators (39) , this is the first cell cycle regulatory gene shown to be essential for both spermatogenesis and oogenesis.
The male germ-cell specific and Cdk2 regulatory partner cyclin A1 is also essential for spermatogenesis during prophase I (71). However cyclin A1 knock-out spermatocytes progress normally up to the transition from prophase to metaphase. They stop just before metaphase I due to their inability to activate the Cdk1-cyclin B complex (72) . Nevertheless, unlike in Cdk2 knock-out mice, the chromosomes undergo normal synapsis in the absence of cyclin A1. Therefore, Cdk2 must have a function in spermatogenesis, earlier in the meiotic prophase I, that is independent of cyclin A1.
A search for meiotic substrates of the Cdk2-cyclin A1 complex has provided a new clue of what a function of Cdk2 may be in spermatogenesis and perhaps a more general function of Cdk2 in DNA double strand break repair. A triple hybrid screening in yeast has shown that the Ku70 protein, one of the subunits of the DNA-PK complex involved in DNA repair, interacts with and is phosphorylated by Cdk2-cyclin A1 (73, 74) . Similarly, recent data indicate that BRCA2, a protein involved in DNA repair by homologous end joining is phosphorylated by either Cdk1 or Cdk2 and this phosphorylation modulates the binding of BRCA2 to Rad51 (75) . Massive double strand brake activity and repair by homologous recombination are some of the hallmarks of the prophase I of meiocytes. Whether Cdk2 is involved in double strand brake repair in meiosis requires further investigation.
E-cyclins are dispensable for most, if not all, embryonic develoment but required for placental function
The unexpected finding that murine Cdk2 was overtly dispensable for cell cycle progression and embryonic development was accompanied by another equally surprising result coming from the generation of mice devoid of the E-type cyclins (76, 77) . The comparison of the phenotypes of these two models has brought to light very intriguing Cdk2-independent functions of the E-type cyclins with profound implications for cell cycle regulation.
Both cyclin E1 and E2 share significant amino acid homology and are expressed in an overlapping manner in virtually all proliferating cells (78) . With the exception of a 50% male infertility in cyclin E2 null mice, individual deletion of either gene has no significant phenotypical consequences. Actually, mice carrying a single wild-type allele encoding cyclin E1 and null for cylin E2 also develop to term and are born at Mendelian ratios with males showing a more pronounced infertility phenotype compared to cyclin E2 single null males. Therefore, either the two Etype cyclins perform overlapping functions and a single cyclin E allele is sufficient for proliferation and normal embryonic development, or alternatively, cell proliferation and development of most embryonic tissues may not require E-type cyclins.
A preliminary analysis rejected the latter explanation as no cyclin E1 and E2 double knock-out mice were born alive and embryonic lethality was estimated to occur at around E11.5. However, at this stage double knock-out embryos, albeit showing some growth retardation, displayed normal organogenesis and morphogenesis and even their proliferative rate mirrored that of wild-type littermates as shown by BrdU incorporation (76, 77) . However mutant embryos did show a dramatic defect in their placental structures that resulted in reduced vascularization of the yolk sac and the embryonic tissues. In particular the layer of trophoblast giant cells was nearly absent in the placentas of mutant conceptuses which instead contained a layer of underdeveloped trophoblastic cells. Given the pivotal role of this cell type in placental physiology this defect was likely the cause of death of cyclin E deficient mice.
But should this hypothesis be valid the embryonic development of mutant mice could in principle be recovered by tetraploid complementation rescue. In this method wild-type two-cell embryos are fused by an electric shock giving rise to a tetraploid embryo that eventually develops into a blastocyst. Mutant embryonic stem (ES) cells are injected into these tetraploid blastocysts that are then implanted into foster females. Importantly, tetraploid blastocysts fail to contribute to the embryo proper but yet form normal placentas and other extraembryonic tissues (79, 80) . Geng and co-workers applied this method with several ES cell lines established from double mutant cyclin E1 and E2 null blastocysts and managed to fully rescue the embryonic lethality of cyclin E deficient mice (76). This approach not only proved that the embryonic lethality was indeed due to a placental dysfunction but remarkably, that the entire embryonic development can occur in a cyclin E independent manner. This, however, does not apply to the cardiovascular system. Up to 50% of the rescued mutant embryos died perinatally due to multiple cardiac abnormalities, preventing the characterization of cyclin E deficiency in adult mice. As all embryos generated by tetraploid rescue die soon after birth unless they are originated from hybrid ES cells (81) , the question remains of whether the lethality in tetraploid rescued cyclin E null fetuses and newborns is due just to the lack of E-cyclins or the consequence of other genetic or epigenetic abnormalities of the established ES cells. Nevertheless this result demonstrated that cyclin E plays a role in placental development that is independent of Cdk2, as no abnormalities are found in placentas of Cdk2 null mice.
The placental dysfunction in cyclin E null mice is itself very interesting. It is caused by a defect in the trophoblast giant cells present in this organ (76) . These cells normally undergo a process known as endoreplication: repeated rounds of DNA synthesis without intervening mitoses leading to increases in DNA content up to 1000N. In this particular cell type the process of endoreplicaton has been postulated to rely on the inhibition of cyclin B1 translation (82) . Remarkably, the increment on DNA content fails to occur in the absence of cyclin E suggesting that cyclin E is essential for endoreplication (76, 77) .
In addition to trophoblast giant cells, megakaryocytes also undergo endoreplicative cycles.
Rescued cyclin E deficient embryos permitted the analysis of this cell type and revealed that the absence of E-type cyclins also impaired the increment of DNA content in this cellular context (76) . Importantly, cyclin E has been previously implicated in endoreplicative cycles of a very different cellular setting, namely that of Drosophila salivary glands (83) . The phenotype of cyclin E-null mice clearly demonstrates that in mammals cyclin E is essential for endoreplication and that this function is independent of Cdk2 ( Figure 2 ).
E-cyclins but not Cdk2 are required for entering S-phase from quiescence
Importantly, the tetraploid complementation strategy also makes possible the isolation of primary MEFs derived from rescued cyclin E null embryos. MEFs lacking E-cyclins proliferate normally in continuous culture and only show a negligible increase in their population doubling time together with a precocious entry in senescence. This behaviour very much parallels that of Cdk2 knock-out primary MEFs which also proliferate normally, as expected from the phenotype of Cdk2 null mice (60, 61) .
However, the comparison between these two types of MEFs produced a perplexing finding when their ability to exit quiescence was analysed. While Cdk2 null MEFs, and only in the case of late passage cells, barely showed a slight impairment to exit G0 and enter S-phase, cyclin E deficient cells completely failed to do so, despite of the fact that they showed normal levels of cyclin Aassociated kinase activity and pRb phosphorylation. Indeed these cells responded normally to mitogenic stimulation activating the E2F transcriptional program but, unlike Cdk2 null MEFs, they remarkably failed to progress into S phase (76) . This finding clearly demonstrated that E-cyclins play an additional and essential role in the G0 to S transition that is Cdk2-independent, and that seems to be related to a specific activity of the E-cyclins directly in the initiation of DNA replication (Figure 2 ). This role can not be assumed by other cyclins, or other unrelated proteins, in the absence of cyclin E.
The competence of eukaryotic chromosomes to replicate is established by the ordered assembly of a multiprotein complex (pre-replicative complex or pre-RC) at the still ill defined origins of DNA replication (for a detailed review see 84) . The process begins with the binding to the replication origins of a group of proteins known as the origin recognition complex (ORC) that subsequently allow recruitment of the initiation factors Cdc6 and Cdt1. These, in turn, are both required for the loading of the heterohexameric MCM2-7 complex. This is a crucial event as once the MCM complexes are loaded onto chromatin the other pre-RC components are dispensable for replication initiation during S phase entry (85) . In quiescent mammalian cells, that are serum stimulated to re-enter the cell cycle, pre-RC assembly occurs in late G1 phase (86) . And it is here where puzzling differences first appear between Cdk2 and cyclin E deficient cells.
Geng and co-workers have shown that cyclin E null MEFs fail to load the MCM proteins onto chromatin despite having normal levels (and timing) of ORC and Cdc6 binding (76) . This observation is not without precedent: in quiescent 3T3 nuclei induced to replicate in a cell-free system, cyclin E is required for loading MCM proteins onto chromatin (87) . In these experiments the positive role exerted by cyclin E was believed to depend on Cdk2 (cyclin E alone was not tested nor the experiments performed in the presence of Cdk inhibitors). Consequently Cdk2-cyclin E was assumed to be required to phosphorylate MCM proteins and/or to inactivate an inhibitor of this process. However, it has now become clear that this is not the case and that cyclin E plays a critical, Cdk2-independent function. Interestingly, DNA replication occurs normally in continuously proliferating cyclin E deficient cells suggesting that the molecular aspects of pre-RC formation differ depending on whether cells emerge from M or G0 phases when they enter S-phase.
It is then tempting to assume that both the inability of cyclin E deficient MEFs to enter S phase from G0 and the endoreplicative defect seen in cyclin E null mice are due to the same cause: a defective binding of MCM proteins to the replication origins. In support of this hypothesis is the finding that, during the endoreplication cycle of Drosophila´s salivary gland cells, cyclin E is implicated in promoting the relocalization of the MCM proteins to DNA replication origins (83) .
On balance, the differences between cyclin E and Cdk2 knock-out models bring up an intriguing query. Etype cyclins have no known catalytic partners in addition to Cdk2 and Cdk3, and the latter is non-functional in all laboratory mouse strains (10) . Indeed, immunoprecipitates from Cdk2 knock-out cell extracts show no cyclin Eassociated kinase activity, at least when pRb or histone H1 are used as the in vitro substrates (60, 61) . Therefore, either cyclin E has a yet undiscovered catalytic partner or, alternatively, it plays some essential functions that do not involve a kinase activity. Both possibilities are obviously not mutually exclusive and further work needs to be done to learn more about this very intriguing and important question.
Finally, it is important to mention other data in support of Cdk2-independent activities of cyclin E. Matsumoto and Maller have recently described a centrosomal targeting domain in cyclin E, essential for promoting S phase entry in a Cdk2-independent manner (88). Additionaly, the oncogenic activity of cyclin E relies on certain domains of the protein, which are distinct in their function to those mediating binding and activation of Cdk2 (89) . In this respect, as we discuss below, it is of interest to note that the absence of E-type cyclins results in a greatly reduced susceptibility to oncogenic transformation while, significantly, this is not the case with Cdk2 knock-out cells (60, 76) .
G2/M cyclins: essential for proliferation?
Two A-type cyclins, A1 and A2, have been described in mammalian cells and both have been succesfully deleted in mice. While cyclin A1 expression seems to be restricted almost exclusively to the male germ cell lineage in physiological conditions, cyclin A2 is ubiquitously expressed in all cell types from the the very early (four-cell stage) embryo onwards (90) . And, almost as an exception, the phenotype of the individual knock-out mouse strains of these two genes reflect the outcome expected a priori based on their expression pattern.
Cyclin A1 null animals are viable and females are completely normal and fertile. Males, however, display a complete disruption of spermatogenesis due to an arrest before the first meiotic division (71) . Although no other phenotypic abnormalities have been associated to cyclin A1 deficiency, a recent report postulates o role for cyclin A1 in driving cell cycle progression of primary MEFs and also leukemic cell lines where cyclin A1 is expressed (91) .
In contrast to the mild phenotype produced by cyclin A1 disruption in somatic cells, ablation of cyclin A2 in mice results in early embryonic lethality (92) . Cyclin A2 deficient embryos reach the blastocyst stage only to die soon after implantation. Interestingly, both cyclin A2 protein and mRNA of maternal origin are degraded before the embryos reach the four-cell stage, implying that at least early embryonic cycles can occur in the absence of cyclin A2 (92) . This is nonetheless not the case in cultured somatic cells where this cyclin plays a critical and non-redundant role during S and M phase progression (93) underscoring the different molecular requirements for embryonic and adult cell cycles (39) . Generation of a conditional cyclin A2 knock-out mouse strain will undoubtedly help to better characterize the requirement of cyclin A2 for adult cell proliferation.
In addition to the prophase functions ascribed to cyclin A2 (93) , mitotic control primarily relies on B type cyclins complexed to Cdk1. There are three mammalian B type cyclins with quite divergent attributes. Cyclin B1 and B2 show almost ubiquitous expression, but that is where their similarities end. Both proteins differ in their function and this may be partly due to their distinct subcellular localization. Cyclin B1 is a microtubule-associated protein that swiftly translocates into the nucleus prior to nuclearenvelope breakdown (94) . In contrast, cyclin B2 associates with intracellular membranes and is implicated in the reorganization of the Golgi apparatus that takes place during mitosis (95) . Cyclin B1 is an essential gene and knock-out embryos die before mid-gestation while B2-deficient animals display no obvious phenotype and normal lifespan (96) . This, once again, may be due to functional redundancy because cyclin B1 is much more abundant and able to phosphorylate the same Golgi substrates as B2.
The third family member, cyclin B3, is by far less studied. It is a Cdk2-interacting nuclear protein expressed in testes and also fetal ovaries (97) . Although there is speculation that it may be implicated in meiosis this still requires further characterization and so far no cyclin B3-null mice have been reported.
Tumorigenic properties of cyclins and CDKs
Cancer is often referred to as a cell cycle disease. Uncontrolled proliferation, genetic instability and aberrant chromosome segregation, blueprints of cancer cells, are often associated to deregulation of genes involved in cell cycle control. Not only cyclins and Cdks are often target of genetic alterations in cancer themselves but mutations that affect a wide variety of signal transduction pathways ultimately lead to a deregulation of the core machinery that drives cell cycle progression and therefore to deregulation of the Cdk activity. It is not a surprise then that the pRb pathway, the major regulator of cell cycle entry from quiescence, is one of the most frequent targets of genetic alterations in tumors (98) , and therefore the Cdks that control pRb function at the G0 to S transition, mainly Cdk4, Cdk6 and Cdk2 have been long considered potential targets for therapeutic intervention in cancer. Moreover, the existence of natural inhibitors of these Cdks, the INK4 and Cip/Kip proteins, that have a negative effect on cell proliferation, has encouraged the pharmaceutical industry to search for small compounds that exert the same effect on cell proliferation by inhibiting Cdk activity.
The implication of the individual cyclins and Cdks in tumor development and their therapeutic potential as targets for anti-cancer drugs needs to be revised according to recent findings in transgenic and gene targeted mice.
Lessons from transgenic mouse models of cyclins and Cdks
Molecular analysis of human tumors has shown that cyclins and Cdks are often overexpressed in tumor cells. However, it has been hard to establish a causal relationship between overexpression of these genes and tumor development. Transgenic mice have been generated to study the tumorigenic potential of the overexpressed cyclins and Cdks in vivo using different tissue-specific promoters.
Although these models are informative, intrinsic limitations are always associated to them. For instance, overexpression of a certain gene may interfere with the normal regulation of another gene of the same family; unrelated pathways may be also affected by transgene overexpression; ectopic expression of the transgene is a common phenomenon in these models and can lead to data missinterpretation; comparison between different models is not straight forward as phenotypes may depend on promoter specificity, expression levels etc. In spite of these drawbacks, and even when transgenic models are just an aproximation to the real pathology found in human tumors, these models are valid for testing the transforming potential of cyclin and cdk genes in vivo and for the development of new therapies targeting cell cycle genes to interfere with cell proliferation. D-cyclins are commonly found overexpressed in tumors, often associated to chromosomal alterations including translocations and gene amplifications. Breast tumors show a particularly high incidency of cyclin D1 overexpression, approximately 50%. Cyclin D2 and D3 have also been found amplified and overexpressed in different types of human cancer (reviewed in 99).
Overexpression of cyclin D1 in the mammary gland of transgenic mice under the control of the MMTV promoter causes constitutive mammary hyperplasia. Multifocal lessions and metastasis, albeit with low incidency, are observed in older mice. These results suggest that cyclin D1 overexpression contributes to breast cell transformation but other genetic events are also required (100).
The tumorigenic properties of D-cyclins in breast are not restricted to cyclin D1. Overexpression of cyclin D2 in transgenic mice under the control of the same promoter (MMTV) results in a similar phenotype. Thus, the long term expression of cyclin D1 or cyclin D2, together with other genetic events, induces mammary tumorigenesis in mice. However, interestingly, the earlier phenotypic consequences of cyclin D2 overexpression in the mammary gland are similar to those found in cyclin D1 knock-out mice: inhibition of normal alveologenesis and nursing in pregnant females, without associated developmental alterations (101) . In fact, this phenotype seems to be, at least partially, due to a "dominant negative-like" effect of cyclin D2 over the normal cyclin D1 activity. This is in sharp contrast with the complete rescue of the cyclin D1 knock-out breast phenotype by expressing the cyclin D2 cDNA in place of cyclin D1 using a knock-in strategy (41) . This model differs from the cyclin D2 transgenic model in that cyclin D2 expression replaces the endogenous expression of cyclin D1. This is an example of how in tissues highly dependent on a particular cyclin activity, as the mammary gland is on cyclin D1, any distortion from the physiological regulation of this pathway interferes with normal development. As discussed below, the importance of cyclin D1 in breast tissue proliferation is underscored by the observation that lack of cyclin D1 selectively prevents tumor development originated by alterations in the Ras and Wnt pathways, both of them involved in cyclin D1 induction.
However, not all tissues are equally sensitive to overexpression of cyclin D1. Transgenic mice overexpressing cyclin D1 in lymphocytes under the control of the Eµ promoter did not exhibit lymphocyte hyperplasia (102) . Therefore, cyclin D1 overexpression per se is not enough to induce lymphocyte proliferation. Nevertheless, overexpression of cyclin D1 in mice doubly transgenic for cyclin D1 and Eµ-myc leads to accelerated development of lymphoma. This result further supports the conclusion that activation of the cyclin D1 cooperates with other oncogenic pathways to promote tumorigenesis.
Other transgenic mouse models for D-cyclins have also been generated (103, 104) , but they are not within the scope of this discussion.
Like their regulatory partners, Cdk4 and Cdk6 are also target of genetic alterations in cancer. Cdk4 is amplified and overexpressed in a variety of tumors from different cellular origins. Cdk6 is also upregulated by gene amplification in squamous cell carcinomas and gliomas and is frequently found overexpressed in lymphoid tumors often associated with chromosomal translocations (reviewed in 105).
Cdk4 has been overexpressed in transgenic mice in the basal cell layer of the skin under the control of the K5 promoter (106) . The epidermis of these mice shows a normal pattern of epidermal differentiation. Although the mice develop epidermal hyperplasia, hipertrophy and dermal fibrosis with age, they do not develop skin tumors. However, these mice are more susceptible to tumor development when subjected to the classical skin carcinogenesis protocol (DMBA initiation followed by TPA promotion) that normally leads to oncogenic H-ras activation. Overexpression of Cdk4 increases the rate of malignant progression from papillomas to squamous cell carcinomas in DMBA/TPA treated transgenic mice, which indicates that Cdk4 upregulation cooperates with ras oncogenes in skin tumorigenesis.
Interestingly however, double transgenic mice for both Cdk4 and cyclin D1 did not show increased malignant tumor formation compared to Cdk4 single transgenics, suggesting that either the oncogenic properties of Cdk4 are not entirely dependent on cyclin D1 (another D-cyclin could be activated by Cdk4 in this model) or the expression level of cyclin D1 in the epidermal cells is not rate limiting to titrate all the exogenous Cdk4. In support of the latter is the finding that cyclin D1 overexpression under the control of the same promoter does not affect tumor development induced by DMBA/TPA in the skin (107).
Cyclin E1 is also amplified and overexpressed in human tumors (reviewed in 32), particularly, in breast tumors and breast cancer cell lines. Interestingly, in addition to overexpression of full length cyclin E1 some of these tumors express up to five different short isoforms of cyclin E, generated by elastase-mediated proteolysis of the N-terminal portion of the protein followed by posttranslational modifications (108, 109) . These short forms are hyperactive compared to the long form, and are resistant to p27 Kip1 and p21 Cip1 inhibition (110) . Overexpression of the short forms of cyclin E in breast tumor cell lines such as MCF7 induced increased polyploidy and chromosome instability (109) , and their presence is considered a significant predictor of poor prognosis in breast cancer (111) .
Transgenic mouse models have been generated to study the implication of cyclin E in breast tumors. Overexpression of human full length cyclin E in the epithelial cells of the mammary glands of pregnant and lactating mice under the control of the ovine betalactoglobulin gene promoter leads to epithelial cell hyperplasia after the first lactation cycle. In most transgenic mice the hyperplastic structures were eliminated after mammary gland regression. Yet, aproximately 10-15% of mice developed mammary gland carcinomas (112) . Tumor development in this model, however, is strain dependent. In a C57BL/6 background no tumor development was observed indicating the existence of modifier genes for the tumorigenic phenotype.
Overexpression of either cyclin D1 or cyclin E in the mammary gland of mice, therefore, results in hyperplasia and tumor formation. This is consistent with a linear functional pathway for these two cyclins as shown by the rescue of the breast phenotype of cyclin D1 knock-out mice by knocking-in the cyclin E cDNA in the locus encoding cyclin D1 (22) . However, the phenotypes of both transgenic models are significantly different. In MMTVcyclin D1 transgenic mice, hyperplasia is detected after 2 months of age, before pregnancy, while in cyclin E transgenics hyperplasia is dependent on pregnancy and lactation and the incidency of tumors is lower. This probably reflects different promoter activity and/or specificity. Alternatively, cyclin D1 may have other activities in breast independent of cyclin E activation. In this line, Cdk4-independent activation of estrogen receptor by cyclin D1 has been described (113) and could contribute to the tumorigenic properties of cyclin D1 in the breast.
As in the case of D-cyclins, tumorigenesis induced by cyclin E overexpression is cell type-dependent. Transgenic mice that express high levels of cyclin E in T cells under the control of the CD2 promoter did not develop lymphoid neoplasia, but were more susceptible to tumor development after treatment with methyl-nitroso-urea (114) . Moreover, in the absence of p27
Kip1 these mice developed monoclonal T-cell lymphoma after a latency period of about seven months. This result indicates that both events cooperate in lymphomagenesis (115) and correlates with the presence of high levels of cyclin E and low levels of the p27
Kip1 protein often found in human Tcell lymphomas.
Cyclin A1 has been found overexpressed in leukemias and testicular cancers. Cyclin A1 transgenic models have also been produced to test the capacity of this cyclin to act as an oncogene. The wild-type and a proteasome resistant mutant form of cyclin A1 have been expressed in the mammary gland of mice under the control of the ovine beta-lactoglobulin gene promoter (112) . Transgenic mice showed nuclear abnormalities such as multinucleation and karyomegaly suggestive of preneoplastic alterations. These abnormalities were more severe when a proteolysis resistant mutant form of cyclin A1 was expressed. Co-expression of Cdk2 and cyclin A1 in double transgenic mice exacerbated the phenotype suggesting that these two genes cooperate in cellular transformation or that, in this case, cellular cyclin A levels are indeed rate limiting for cell proliferation in the mammary gland.
Tumor suppressor properties of INK4 and Cip/Kip cell cycle inhibitors
The relatively mild tumorigenic phenotypes induced by overexpression of cyclins and Cdks in transgenic mice are in contrast with the more severe phenotypes observed in models where the control of Cdk activity by INK4 or Cip/Kip proteins is partially or completely lost, underscoring the importance of this control in cell proliferation and cell transformation. ) by deletion, promoter methylation and/or point mutations has been found in a wide variety of human tumors (117) . All the INK4 genes have been knocked-out in mice, and in parallel with what is found in humans, with the exception of p19
INK4d , all these proteins act as tumor suppressors in mice (Table 3 ).
The relevance of the cell cycle control by the INK4 family of cell cycle inhibitors in tumor suppression is best illustrated by the phenotype of the Cdk4R24C knock-in mouse strain described above. Biochemically this mutation makes Cdk4 unable to interact with cell cycle inhibitors of the INK4 family, and therefore yields it resistant to negative control by these proteins. Importantly this mutation does not seem to affect either the ability of Cdk4 to interact with D-cyclins or its kinase catalytic domain. (118, 119) . Knock-in mice were generated to test the ability of this mutant form of Cdk4 to function as an oncogene in vivo (Rane et al. 1999) . A floxed neo cassette was inserted into the first intron in opposite transcriptional orientation to that of the Cdk4 gene (Cdk4 neo allele). This resulted in the abolition of Cdk4 expression. When the neo cassette is removed by the Cre recombinase the resultant allele expresses the mutated form of the Cdk4 protein, Cdk4R24C. Mice heterozygous or homozygous for the knock-in allele, expressing endogenous Cdk4R24C in the germ line, develop multiple tumors of diverse origin, including pituitary tumors, with 100% penetrance (46, 120), demonstrating that loss of INK4 inhibition of Cdk4 activity leads to tumor development. Although this mutation of Cdk4 was first identified in human melanoma, Cdk4R24C knock-in mice do not develop this type of tumor spontaneously, but they do after treatment with the skin carcinogenic protocol DMBA/TPA (121) , showing that loss of Cdk4 inhibitors cooperates with H-ras mutations in melanoma development. This correlates with the observation that transgenic H-ras expression in melanocytes of mice lacking the locus INK4a also leads to melanoma development (122) .
Within the Cip/Kip protein family, p21
Cip1 and p57
Kip2 are rarely found altered in human cancer. On the other hand, although not a genetic target in cancer itself, p27
Kip1 protein levels are frequently reduced in human tumors and tumor cell lines. Reduced level of p27 Kip1 protein is related to bad prognosis of a wide variety of tumors including breast, prostate and gastric carcinomas, among others (123, 124) .
The phenotypes of single INK4 or Cip/Kip gene knock-outs or combinations of them, as well as the implication of these genes in human tumors has been reviewed elsewhere (38, 105 ) and we will not discuss them here. However, the major phenotypes of these models in development and cancer are summarized in Table 3 .
Mice lacking D-cyclin-dependent signalling are resistant to cancer
Up-regulation of cyclins and Cdks predisposes to tumor development as described above. However, the question remains as to whether inhibition of Cdk activity is an effective therapy for cancer. In the adult organism, most cells are in a quiescent, non proliferative, state. Tumor cells, however, proliferate very actively. So, in principle, tumor cells will be more dependent than normal mature cells on Cdk-cyclin activity as they have to efficiently progress through the cell cycle, replicate their DNA and ultimately divide. Cdk activity, therefore, would be an ideal target for cancer treatment as it would be a priori dispensable for normal quiescent adult cells but essential for tumor cells. Different experimental approaches, using loss of function mouse models of cyclins and Cdks, have provided some genetic clues to help validating these proteins as targets for cancer therapy.
A relatively simple and widely used strategy is to test the sensitivity of primary cells, obtained from knockout mice, to oncogene-induced transformation. The standard primary cell-type used for transformation assays is MEFs. Wild-type MEFs can be transformed by ras in combination with other oncogenes such as myc, adenovirus E1A or dominant negative (DN) p53. Transformed MEFs loose contact inhibition and anchorage dependent growth. They become able to form colonies when grown in soft agar, and tumors when injected in immunodeficient mice.
MEFs lacking all the three D-type cyclins are resistant to transformation induced by any of the oncogene combinations that transform wild-type cells while MEFs lacking only cyclin D1 are not (51), probably due to functional redundancy with cyclin D2 or D3. This is an intriguing finding, as MEFs lacking D-type cyclins can proliferate and enter cell cycle from quiescence, although less efficiently than wild-type cells. A possible explanation is that D-cyclins are required for cells to respond effectively to the strong and constitutive mitogenic stimulation required for cell transformation in vitro, although they can reach the threshold of kinase activation required for normal proliferation in the absence of Dcyclins. This theory is supported by the finding that highly proliferative tissues such as the fetal haematopoietic system, but not others, are those affected by the lack of Dcyclins or cyclin D-dependent Cdks, as previously discussed.
MEFs lacking Cdk4, although they still express Cdk6, are also resistant to transformation by ras and DN p53, (125) indicating that Cdk6 by itself is not enough to sustain cell transformation. Cdk4 is also required for long term proliferation of MEFs. MEFs without Cdk4 senesce in culture more rapidly and become immortalized less frequently than wild-type MEFs. This phenotype becomes more severe in the absence of both Cdk4 and Cdk6 (50) . It could be anticipated that MEFs lacking both Cdks will be also resistant, as D-cyclin deficiente MEFs are, to oncogenic transformation, but this still remains to be determined.
How do the results in MEFs translate to tumor development in vivo? First, the absence of D-cyclins makes mice more resistant to tumor development. For instance, cyclin D1 knock-out mice become resistant to intestinal tumors induced by beta-Catenin or Apc (adenomatous polyposis coli) loss (126) , to skin papillomas induced by HRas activation (127) and to breast tumors induced by Ras or Neu activation (128) . However the response of tumors to cyclin D1 inactivation is dependent on the oncogenic pathway by which tumors are driven. Thus, cyclin D1 knock-out mice are as sensitive as wild-type mice to breast tumors driven by c-Myc or Wnt-1 (128) . This result indicates that the mitogenic Neu-Ras pathway connects with the cell cycle through cyclin D1 activation in the mammary epithelium and therefore cyclin D1 is absolutely required for cell transformation in tumors driven by constitutive activation of this pathway.
It would be interesting to test whether or not mice lacking Cdk4 are as resistant to tumors as those lacking cyclin D1 are, or alternatively, other Cdk4-independent activities of cyclin D1 contribute to the tumorigenic phenotype. Against the latter is the finding that a gene replacement knock-in model expressing cyclin E in the cyclin D1 locus is no longer resistant to Ras induced breast tumors, demonstrating the linearity of the cyclin D1-cyclin E pathway to drive cell proliferation and cell transformation induced by Ras activation in the mammary epithelium.
Cyclin D2 and D3 ablation also protects mice against certain types of tumors. Mice lacking cyclin D2 are more resistant to gonadal tumors (129) and mice lacking cyclin D3 are more resistant to leukemias driven by Notch and thymomas induced by p56LCK (130) .
Cdk4 ablation also confers resistance to certain tumors in mice. For instance it interferes with skin carcinogenesis induced by Ras activation (131) and to skin tumors driven by a K5-c-myc transgene (132) .
These results suggest that, at least in certain types of tumors, for instance those driven by ras oncogene activation in breast or skin, interfering with Cdk4-cyclin D activity may be effective as an anti-cancer therapy. However this needs to be taken with caution. Ablation of cyclin D or Cdk4 in the germ line may not have the same consequences for tumor development than their inactivation in tumor cells. In this respect, we have already mentioned that lack of D-cyclins or Cdk4 activity reduces the life span of primary MEFs, thus it is possible that the tissue stem cell proliferative potential in germ line knock-out models may be limited by the lack of D-cyclins or Cdk4 from early development, or even that a subset of those stem cells be absent. If this is the case, and this is the major reason why tumors do not develop in the knock-out mice, inhibiting cyclin D or Cdk4 in the tumor could not effectively ablate tumor progression. Conditional models of cyclin D and Cdk4 inactivation that allow to inhibit this pathway in adult mice will help to address these issues.
Lack of E-cyclins but not Cdk2 confers resistance to oncogenic transformation
MEFs lacking E-cyclins (double null for cyclin E1 and E2) are also resistant to oncogenic transformation by a combination of ras plus an immortalizing oncogene (76) . In principle, the resistance to oncogenic ras activation in these cells could be potentially explained, as in the case of MEFs lacking D-cyclins, by the inability of these MEFs to reach the threshold of kinase activation required for cell transformation in the absence of E-cyclins. However, in this case the complete resistance to oncogenic tranformation of E-cyclin knock-out MEFs contrast sharply with the mild resitance observed in MEFs lacking Cdk2 (60) . Cdk2 null MEFs can be transformed by ras and adenovirus E1A although with about 30% less efficiency than wild-type MEFs. These results indicate that cyclin E plays roles in cell transformation that are independent of Cdk2, and as Cdk2 is the only known partner of cyclin E, a lower threshold of kinase activity may not to be a valid explanation for the resistance to transformation found in the absence of E-cyclins.
Previous data had shown that mutant forms of cyclin E that fail to form an active kinase complex with Cdk2, are able to transform rat embryo fibroblasts in cooperation with H-ras (89) . Therefore it had been proposed that cyclin E harbors other functions, independent of Cdk2 activation and p27 Kip1 binding, that contribute to its oncogenic activity. Comparison of the phenotypes of cyclin E and Cdk2 knock-out mice has in fact revealed Cdk2-independent functions of cyclin E in DNA endoreplication and in entering S-phase from quiescence. In the latter process, cyclin E is essential for the incorporation of MCM proteins to the PRcomplexes at the origins of replication. Whether this Cdk2-independent activity of cyclin E is required for cellular transformation remains to de determined.
The results in MEFs suggest that interfering with E-cyclin activity, somehow, may be a good strategy for cancer intervention. This needs to be further supported by studies in vivo, similar to the ones described for D-cyclins. However, these studies are precluded by the embryonic lethality of mice lacking E-cyclins, and require the generation of conditional knock-out models.
Cdk2 had itself long been considered a good target for cancer therapy and a long list of Cdk2 inhibitors developed by the pharmaceutical industry already exist. The concept of Cdk2 being essential for proliferation was originated by early experiments in tumor cell lines showing that inhibition of Cdk2 by different strategies blocked cell proliferation while inhibition of Cdk4 activity in the same conditions did not (57) . However, the fact that Cdk2 knockout MEFs can be transformed by oncogenes suggests that interfering with Cdk2 activity by itself is not efective to inhibit tumor development. Although more studies need to be undertaken to better understand the implication of Cdk2 in tumor growth, in the next section we revise recent in vivo data that further support the concept of Cdk2 activity being dispensable for tumor development.
The tumor suppressor actvities of p21
Cip1 and p27
Kip1 are Cdk2-independent The dispensability of Cdk2 for cell proliferation and oncogenic transformation, demonstrated by gene targeting of Cdk2 in the mouse, rises the important question of whether in fact the molecular mechanisms involved in cell cycle inhibition and tumor suppressor activities of p21
Cip1 and p27 Kip1 rely on the inhibition of Cdk2. Recently this question has been addressed by Barbacid´s group (133) . Double mutant mice, lacking either p21
Cip1 and Cdk2 or p27
Kip1 and Cdk2, have been generated by intercrossing the individual null strains and MEFs have been isolated from these mice. MEFs lacking p21
Cip1 or p27 Kip1 have the same proliferative advantages independently of whether or not Cdk2 is present. Similarly, retroviral overexpression of p21
Cip1 or p27 Kip1 in MEFs exerts the same antiproliferative effect in the presence than in the absence of Cdk2. Moreover, p21
Cip1 -mediated cell cycle arrest in response to DNA damage in MEFs is also independent of Cdk2 (133) . Therefore, these results clearly establish that at least in MEFs, Cdk2 is not required for cell cycle arrest induced by p21
Cip1 or p27 Kip1 .
The same conclusion has been reached from in vivo experiments. Mice lacking p27
Kip1 and Cdk2 exhibit organomegaly and develop pituitary tumors at the same rate and with the same incidency as mice lacking only p27 Kip1 (133) . These results indicate that a Cdk2-independent mechanism is responsible for the in vivo growth inhibitory and tumor suppressor activities of p27 Kip1 . As mentioned above, many human tumors show reduced levels of p21 Cip1 and p27 Kip1 . These results argue against the adequacy of Cdk2 inhibition as a strategy for therapeutical intervention in these tumors.
The mechanism by which p21
Kip1 inhibit cell growth in the absence of Cdk2 remains obscure. Both proteins bind to Cdk1 and inhibit its kinase activity (134, 135) . Therefore, Cdk1 inhibition could mediate some of the effects of these proteins on cell proliferation. In support of this hypothesis, expression of a p27 Kip1 mutant form, lacking a functional Cdk binding domain, is no longer able to suppress cell proliferation in the same experimental setting, in the presence or in the absence of Cdk2 (133) . However Cdk-independent activities of these proteins or their implication in processes other than cell cycle regulation can not be completely ruled out. In fact, the concept of Cdk-independent activities is now emerging for some of the Cdk activators and inhibitors: cyclin D1 binds and activates estrogen receptor independently of Cdk4; similarly, cyclin D1 can modulate the activity of Myb transcription factors in the absence of Cdk4 binding (136, 137) ; comparison of the phenotypes of Cdk2 and cyclin E lacking mice suggests that cyclin E may participate in the initiation of DNA replication as well as in cell transformation, molecular mechanisms that are independent of its catalytic partner Cdk2 (76, 77) . Similarly there may be other targets responsible of mediating the cell proliferation block and tumor suppression activities of p27
Kip1 and p21 Cip1 .
SUMMARY AND PERSPECTIVES
Mouse models are a powerful tool to study gene function in vivo. Recently the analysis of gene targeted and transgenic mice of cyclins and Cdks and of their inhibitors the Cip/Kip or INK proteins, has provided new information about cell cycle regulation and the control of cell proliferation in mammalian cells.
Most of the cyclins and Cdks, previously considered essential for cell proliferation, have turned out to be dispensable. The case of Cdk2 was particularly unexpected, as it results to be dispensable for most, if not all, somatic cells in the mouse. The surprise promoted by this finding could possibly be atributed to the over-generalization of previous data obtained from experiments in yeast and in tissue culture cells. Potential reasons for the lack of more severe phenotypes in individual gene knock-out mice include lack of expression of some genes in certain cell types, functional redundancy among family members and the activation of compensatory mechanisms, for instance ablation of two of the three D-cyclins leads to ectopic expression of the third one in some cell types. Nevertheless, individual cyclins and Cdks are essential in specific cell-types; even Cdk2 is essential in meiocytes, both in males and females.
In some cases, the results obtained from mouse models confirm previous biochemical and tissue culture data. For instance, ablation of D-type cyclins leads to the same phenotype as ablation of their catalytic partners Cdk4 and Cdk6. In other cases, the opposite is found: ablation of the E-cyclins has different phenotypical consequences than ablation of their only known partner Cdk2, demonstrating that cyclin E may have other interacting partners or other non-catalytic functions, that are still to be revealed.
Analysis of the mouse mutant phenotypes has also provided information about the cell-type specific molecular interactions that take place in vivo. For instance, beta cell proliferation seems to be mediated mostly by Cdk4-cyclin D2 complexes, as mice lacking either of them show similar phenotypes in beta cells; similarly, body size, in terms of cell numbers, is likely to be controlled primarily by Cdk4 and cyclin D1; ablation of p27 Kip1 rescues some of the phenotypes of cyclin D1 knock-out mice, demonstrating the genetic interaction between these proteins in vivo.
Linear pathways of proliferation control, for instance NeuRas-cyclin D1-cyclin E in the mammary epithelium, RasCdk4-cyclin D1 in the skin or Apc-cyclin D1 in the intestine, among others, can also be demonstrated by genetic analysis in mouse models.
Most of the cyclin and Cdk knock-out models that have been generated so far are constitutive knock-outs, resulting in the complete absence of a particular protein, from embryonic day one. As powerful as they are, these models have also some limitations. One of them, already mentioned, is the potential activation of compensatory mechanisms during embryonic development. Moreover, the phenotype observed in each particular case corresponds to the first non redundant and uncompensated function of the gene, obscuring other phenotypes that may appear later during development or producing secondary effects that sometimes are dificult to characterise as such. But in terms of elucidating the implication of cyclins and Cdks in tumor development the limitation of these models is more evident. Even in those cases where the constitutive inactivation of the gene is viable, inhibiting a particular protein in tumor cells is not equivalent to it being absent from the beginning of development. Models in which Cdk-kinase activity is abolished by point mutations, or Cdk/cyclin interactions with cell cycle inhibitors modified, or conditional knockout models in which a particular cyclin, Cdk or cell cycle inhibitor can be especifically ablated in tumors will contribute to improve our knowledge of how the cell cycle control works and how to modify it for therapeutical intervention.
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